Selection of optimal therapy for chronic stable angina

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 1, 2006, Pages 23-35

  Thadani, Udho ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOGENIC PROTEIN; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELIPROLOL; CLOPIDOGREL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; IVABRADINE; MEVINOLIN; NICORANDIL; NICOTINIC ACID; NITRATE; OMEGA 3 FATTY ACID; RANOLAZINE; THIAZIDE DIURETIC AGENT; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL;

ADD ON THERAPY; ANAPHYLAXIS; ATRIOVENTRICULAR BLOCK; BLEEDING; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COLD LIMB; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; COUNTERPULSATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HALLUCINATION; HEADACHE; HEART BLOCK; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; LEG EDEMA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; METHEMOGLOBINEMIA; MUSCLE WEAKNESS; MYALGIA; OPTIMAL DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SPINAL CORD STIMULATION; STABLE ANGINA PECTORIS; SUDDEN DEATH; SYMPATHECTOMY; SYNCOPE; TACHYCARDIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VIVID DREAM;

EID: 31344432933     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0023-9     Document Type: Review

References (57)

1. Thadani U: Chronic stable angina pectoris. In Cardiology. Edited by Crawford MH, et al. Mosby; 2004:257-270.
2. Thadani U: Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther 2004, 9(suppl 1):S11-S29.
3. Abrams J, Thadani U: Therapy of stable angina pectoris: the uncomplicated patient. Circulation 2005, 112:e255-e259.
4. Thadani U: The pursuit of optimum outcomes in stable angina. Am J Cardiovasc Drugs 2003, 3(suppl 1):11-20.
5. Gage JE, Jess DM, Murakami T, et al.: Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986, 73:865-871.
6. Davies MJ, Thomas AC: Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985, 53:363-368.
7. Hinton TC, Chaitman BR: The prognosis in stable and unstable angina. Cardiol Clin 1991, 9:27-38.
8. Thadani U: Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol 1997, 79:24-30.
9. Mark DB, Shaw L, Harrell GE, et al.: Prognostic value of a treadmill exercise score in outpatients with suspected coronary disease. N Eng J Med 1991, 325:849-853.
10. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA/ACP-ASIM. Guideline update for the management of patients with chronic stable angina: summary and abstract. Circulation 2003, 107:143-158.
11. Thadani U: Management of stable angina pectoris. Curr Opin Cardiol 1999, 14:349-358.
12. Asirvatham S, Sebastian C, Thadani U: Choosing the most appropriate treatment for stable angina: safety considerations. Drug Saf 1998, 19:23-44.
13. Heidenreich PA, McDonald KM, Hastie T, et al.: Metaanalysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999, 281:1927-1936.
14. Thadani U: Prevention of nitrate tolerance with angiotensin II receptor type 1 blocker in patients with stable angina: yet another failed strategy to prevent tolerance. Cardiovasc Drugs Ther 2004, 18:339-342.
15. Opie LH: Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996, 38:273-290.
16. Thadani U: Selective L-type, and non-selective calcium channel blockers for stable angina pectoris [editorial]. Am Heart J 2002, 144:8-10.
17. Rehnquist N, Hjemdahl P, Billing E, et al.: Effect of metoprolol versus verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J 1996, 17:76-81.
18. Dargie HJ, Ford I, Fox KM: Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcomes in patient with chronic stable angina. Eur Heart J 1996, 17:104-112.
19. Dunselman P, van Kempen L, Bouwens L, et al.: Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998, 81:128-132.
20. Knight C, Fox K: Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Am J Cardiol 1998, 81:133-136.
21. Akhras F, Jackson A: Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991, 338:1036-1039.
22. Thadani U: Combination therapy. Am Coll Cardiol Curr J Rev 1997, 6:24-25.
23. Strauss WE, Parisi AF: Combined use of calcium channel and beta blockers for the treatment of stable angina, rationale, efficacy and adverse events. Ann Intern Med 1988, 109:570-575.
24. Tolins M, Weir EK, Chesler E, Pierpont GL: Maximal drug therapy is not necessarily optimal in chronic angina pectoris. Am Coll Cardiol 1984, 4:1051-1057.
25. Chavoz EI, Lepakchin VK, Zharova EA, et al.: Trimetazidine in angina combination therapy - the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo controlled, multicenter study. Am J Ther 2005, 12:35-42.
26. Thadani U: Modified release formulation of trimetazidine for exceptional control of angina pectoris: fact or fiction. Am J Cardiovasc Drugs 2005, 5:331-334.
27. Chaitman BR, Skettino SL, Parker JO: Anti-ischemic and long term survival during ranolazine monotherapy in patients with severe chronic stable angina. J Am Coll Cardiol 2004, 43:1375-1382.
28. Chaitman BR, Pepine J, Parker JO: Effects of ranolazine with atenolol, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004, 291:309-316.
29. The IONA Study group: Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002, 359:1269-1275.
30. Thadani U: Can nicorandil effectively treat angina? Nat Clin Pract Cardiovasc Med 2005, 2:186-187.
31. Pepine CJ, Rouleau JL, Annis K, et al.: Effect of angiotensin converting enzyme inhibitor on transient ischemia: the Quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial. J Am Coll Cardiol 2003, 42:2043-2059.
32. Doll R, Peto R: Mortality in relation to smoking: 20-year observations on British doctors. BMJ 1976, 2:1526-1536.
33. Juul-Moller S, Edvardson N, Jahnmatz B, et al.: Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992, 340:1421-1425.
34. Food and Drug Administration: Acetylsalicylic acid and the heart. JAMA 1993, 270:2669.
35. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
36. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003, 289:2560-2572.
37. Vaughan CJ, Gotto AM, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35:1-10.
38. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high risk individuals. A randomized placebo controlled trial [no authors listed]. Lancet 2003, 36:7-22.
39. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program. Adult Treatment Panel III Guidelines. Circulation 2004, 110:227-239.
40. Rubins HB, Robins S, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med 1999, 341:410-418.
41. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (JNCVII) [no authors listed]. Hypertension 2004, 43:1-3.
42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high risk hypertensive patients. Randomized angiotensin-converting enzyme inhibitor, calcium channel blocker vs. diuretic. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2987.
43. Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al.: Markers of inflammation and rapid coronary progression in patients with stable angina pectoris. Circulation 2004, 110:1747-1753.
44. Chaitman BF, Rosen AD, Williams DO, et al.: Myocardial infarction and cardiac mortality in the bypass angioplasty revascularization investigation (BARI) randomized trial. Circulation 1997, 96:2162-2170.
45. Henderson RA, Pocock SJ, Clayton TC, et al.: Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003, 42:1167-1170.
46. Faxon DP: Bringing reality to drug-coated stents. Circulation 2004, 109:140-142.
47. Pitt B, Waters D, Brown WV, et al.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999, 341:70-76.
48. Hambrecht R, Walther C, Mobius-Winkler S, et al.: Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. Circulation 2004, 109:1371-1378.
49. Muneretto C, Bisleri G, Negri A, et al.: Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. Circulation 2003, 108:1129-1133.
50. Kim MC, Kini A, Sharma SK: Refractory angina pectoris. J Am Coll Cardiol 2002, 39:923-934.
51. Thadani U: Patient with disabling angina not amenable to revascularization procedures. In Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. Edited by Theroux P. Philadelpha, PA: WB Saunders; 2003:535-552.
52. Thadani U: Recurrent and refractory angina following revascularization procedures in patients with stable angina [editorial]. Coron Artery Dis 2004, 15(suppl 1):S1-S4.
53. Lawson WE, Hui JC, Cohn PF: Long-term prognosis of patients with angina treatment with enhanced external counterpulsation: five-year follow-up study. Clin Cardiol 2000, 23:254-258.
54. Barsness G, Feldman AM, Holmes DR, et al.: The International EECP Patient Registry (IEPR): design, methods, baseline characteristics, and acute results. Clin Cardiol 2001, 24:435-442.
55. Horvath KA, Aranki SF, Cohn LH, et al.: Sustained angina relief 5 years after transmyocardial laser revascularization with a CO2 laser. Circulation 2001, 104(suppl 1):1-4.
56. Mannheimer C, Eliasson T, Augustinsson LE, et al.: Electrical stimulation versus coronary artery bypass surgery is severe angina pectoris: the ESBY study. Circulation 1998, 37:1157-1163.
57. Braunwald E, Domanski MJ, Fowler SE, et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Eng J Med 2004, 351:2058-2068.